GlassScriptPhysician profile
Ronald G Nahass
NPI 1023084928
$213,269.93
in general payments reported to CMS, 2019-2025
40 companies · $5,176 in 2025
The $5,176 reported for 2025 was more than what 90% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $69K · 2021: $23K · 2022: $34K · 2023: $23K · 2024: $7,948 · 2025: $5,176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Consulting Fee: $7,740 · Food and Beverage: $6,498 · Travel and Lodging: $3,926 · Education: $56.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,600.00 |
| Consulting Fee | $7,740.00 |
| Food and Beverage | $6,497.64 |
| Travel and Lodging | $3,925.93 |
| Education | $56.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $70,489.82 | 2019-2025 | Veklury, Descovy, Biktarvy |
| Viiv Healthcare Company | $62,488.19 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Integra Lifesciences Corporation | $32,470.00 | 2020-2025 | Integra, Surgimend, Codman Certas |
| Abbvie INC. | $23,598.04 | 2019-2025 | |
| Janssen Research & Development, LLC | $8,696.32 | 2019 | |
| Merck Sharp & Dohme LLC | $8,365.98 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Insmed, INC. | $3,973.38 | 2019-2025 | Arikayce, Brinsupri |
| Janssen Products, LP | $295.94 | 2019-2022 | |
| Shionogi INC | $295.38 | 2024-2025 | Fetroja |
| Aimmune Therapeutics, INC. | $274.93 | 2023-2025 | Zenpep, Vowst |
| Janssen Biotech, INC. | $271.31 | 2019-2023 | Symtuza |
| Organogenesis INC. | $260.50 | 2022-2024 | |
| Emd Serono, INC. | $245.43 | 2019-2025 | Serostim |
| Paratek Pharmaceuticals, INC. | $232.10 | 2019-2025 | Nuzyra |
| Melinta Therapeutics, LLC | $171.89 | 2019-2025 | Rezzayo, Kimyrsa |
Show all 39 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$303,690.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Nahass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.